Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893863 | 0.84 | EPHX1 (0.49) | EPHX2SRCMAPK1EPHX1ROCK2 | |
| SCHEMBL4897474 | 0.83 | MTOR (0.56) | EPHX2RAB9ACNR1EPHX1LMNA | |
| SCHEMBL4892249 | 0.83 | FBP1 (0.53) | EPHX2RAB9ACNR1EPHX1ROCK2 | |
| SCHEMBL4892302 | 0.83 | FOLH1 (0.53) | EPHX2EPHX1 | |
| SCHEMBL14088790 | 0.82 | EPHX1 (0.71) | EPHX2RAB9AEPHX1LMNAPOLB | |
| SCHEMBL8178554 | 0.81 | ANPEP (0.54) | ANPEPEPHX2SRCRAB9AMAPK1 | |
| SCHEMBL9269432 | 0.81 | ANPEP (0.58) | ANPEPEPHX2SRCRAB9AMAPK1 | |
| SCHEMBL14088778 | 0.80 | ALDH1A1 (0.64) | ANPEPEPHX2ROCK2LMNAPOLB | |
| SCHEMBL26051555 | 0.80 | ANPEP (0.48) | ANPEPEPHX2SRCRAB9AMAPK1 | |
| SCHEMBL29699631 | 0.78 | SRC (0.61) | ANPEPEPHX2SRCRAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | ANPEP 1718/4885EPHX2 604/4885SRC 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.